featured
Patient-Reported Outcomes Following First-Line Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer